Bloomberg Anywhere Login

Bloomberg

Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.

Company

Financial Products

Enterprise Products

Media

Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000

Communications

Industry Products

Media Services

Follow Us


Last $48.19 USD
Change Today -0.62 / -1.27%
Volume 629.6K
ACAD On Other Exchanges
Symbol
Exchange
NASDAQ GS
As of 5:20 PM 08/3/15 All times are local (Market data is delayed by at least 15 minutes).

acadia pharmaceuticals inc (ACAD) Key Developments

ACADIA Pharmaceuticals Inc. Appoints Ernst & Young LLP as Independent Registered Public Accounting Firm for the Fiscal Year Ending December 31, 2015

ACADIA Pharmaceuticals Inc. has appointed Ernst & Young LLP as its independent registered public accounting firm for the fiscal year ending December 31, 2015 at the annual general meeting held on June 15, 2015.

ACADIA Pharmaceuticals Inc. Presents Integrated Efficacy and Tolerability Data from its Phase III Program with NUPLAZID™

ACADIA Pharmaceuticals Inc. announced the presentation of integrated efficacy and tolerability data from its Phase III program with NUPLAZID™ (pimavanserin) at the 19th International Congress of Parkinson’s Disease and Movement Disorders held in San Diego. An integrated analysis was performed on efficacy and tolerability data from two six-week Phase III placebo-controlled clinical trials with NUPLAZID (40 mg) in Parkinson’s disease psychosis (PDP). In this large pooled sample of 268 patients from North America, NUPLAZID showed highly significant improvement in psychosis compared to placebo on the 9-item SAPS-PD scale (p2A receptors that play an important role in psychosis. ACADIA has reported positive Phase III trial results with NUPLAZID, which has the potential to be the first drug approved in the United States for psychosis associated with Parkinson’s disease. NUPLAZID is administered orally once-a-day. ACADIA discovered NUPLAZID and holds worldwide rights to this new chemical entity. The trade name NUPLAZID has been provisionally accepted by the FDA.

ACADIA Pharmaceuticals Inc. Presents at Jefferies 2015 Global Healthcare Conference, Jun-02-2015 01:30 PM

ACADIA Pharmaceuticals Inc. Presents at Jefferies 2015 Global Healthcare Conference, Jun-02-2015 01:30 PM. Venue: The Grand Hyatt Hotel, New York, New York, United States.

ACADIA Pharmaceuticals Inc. Announces Unaudited Consolidated Earnings Results for the First Quarter Ended March 31, 2015

ACADIA Pharmaceuticals Inc. announced unaudited consolidated earnings results for the first quarter ended March 31, 2015. For the quarter, the company reported collaborative revenues of $4,000 against $30,000 a year ago. Loss from operations was $40,552,000 against $17,958,000 a year ago. Net loss was $40,375,000 against $17,828,000 a year ago. Net loss per common share, basic and diluted was $0.40 against $0.19 a year ago.

ACADIA Pharmaceuticals Inc. Presents at Bank of America Merrill Lynch 2015 Health Care Conference, May-13-2015 04:20 PM

ACADIA Pharmaceuticals Inc. Presents at Bank of America Merrill Lynch 2015 Health Care Conference, May-13-2015 04:20 PM. Venue: Encore at the Wynn, 3131 S Las Vegas Blvd, Las Vegas, Nevada, United States. Speakers: Stephen R. Davis, Interim Chief Executive Officer, Chief Financial Officer, Chief Business Officer and Executive Vice President.

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
ACAD:US $48.19 USD -0.62

ACAD Competitors

Market data is delayed at least 15 minutes.

Company Last Change
Acorda Therapeutics Inc $34.74 USD +0.38
Depomed Inc $31.17 USD -0.33
Impax Laboratories Inc $48.29 USD -0.17
Isis Pharmaceuticals Inc $53.96 USD -0.97
View Industry Companies
 

Industry Analysis

ACAD

Industry Average

Valuation ACAD Industry Range
Price/Earnings NM Not Meaningful
Price/Sales 52,027.8x
Price/Book 17.2x
Price/Cash Flow NM Not Meaningful
TEV/Sales 48,910.7x
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact ACADIA PHARMACEUTICALS INC, please visit . Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.